TROD Medical NV, a leading medical device company developing tools for focal ablation, has announced the completion of enrollment in its clinical study at two world-renown cancer research institutions, University College London (UCL) and New York University (NYU).

The clinical teams at NYU and UCL presented last month at the 111th American Urological Association’s Annual Meeting (San Diego, CA), on patients treated with Encage. Together with a study running at the Moffitt Cancer Center (Tampa, Florida), over 40 patients have now been treated using Encage. Results not yet published show total tissue destruction in target ablation zones and very significant reduction of side effect (erectile dysfunction and urinary incontinence rates down to 0%).

Prof. Mark Emberton from UCL said, “The wonderful thing about Encage is its simplicity. It uses an energy source that clinicians are familiar with and provides very controlled and predictable tissue destruction. It is also extremely versatile in that it can be used to treat small prostate cancers with precision but can also be used to treat the prostate in a zonal manner.”

“Encage is a disruptive technology with the potential to maximize target ablation zones in the prostate while minimizing the all too common side effects associated with current treatments” said Andre Faure, CEO of TROD Medical. He continued, “This significant clinical work at prestigious US and UK institutions builds on the CE Mark Approval for Encage obtained in January 2016, and US FDA 510(k) clearance secured in 2008, and has led to significant attention from major strategic players in urology and surgical oncology.”

TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.